株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ヘリコバクターピロリ感染症:パイプライン分析

Helicobacter pylori Infections - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229761
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ヘリコバクターピロリ感染症:パイプライン分析 Helicobacter pylori Infections - Pipeline Review, H2 2016
出版日: 2016年07月13日 ページ情報: 英文 75 Pages
概要

ヘリコバクターピロリは、胃の中に存在する細菌です。ピロリ菌による感染症は、通常は無症状です。しかし、ピロリ菌が多くの消化器系の異常、例えば潰瘍や胃癌などを引き起こす可能性があります。ヘリコバクターピロリ感染症は、糞便で汚染された食物や水の摂取によって伝染します。胃や十二指腸の細胞を直接または間接的に傷づける特定の酵素や毒素を放出するため、胃や十二指腸の状態に変化をもたらし、その結果、胃潰瘍や十二指腸潰瘍を発症する可能性もあります。最もよく見られる症状として、痛みや不快感(通常は上腹部)、膨満感(少量の食事の後)、食欲不振、悪心や嘔吐、暗黒・タール色の便、出血性潰瘍などがあり、低血球数や疲労を引き起こす場合もあります。

当レポートでは、ヘリコバクターピロリ感染症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

ヘリコバクターピロリ感染症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Daewoong Pharmaceutical Co., Ltd.
  • EpiVax, Inc.
  • ImevaX GmbH
  • ImmunoBiology Limited
  • RedHill Biopharma Ltd.
  • Sequella, Inc.
  • Shanghai Zerun Biotechnology Co., Ltd.
  • Sigmoid Pharma Limited

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (rifabutin + amoxicillin sodium + omeprazole sodium)
  • DWJ-1325
  • FROST-900
  • Helicobacter pylori Hel-305 (multivalent) vaccine
  • helicobacter pylori vaccine
  • helicobacter pylori vaccine
  • helicobacter pylori vaccine
  • helicobacter pylori vaccine
  • HPi-1
  • IMX-101
  • Small Molecules for Helicobacter Pylori Infections
  • Small Molecules to Inhibit DNA Synthesis for Infectious Diseases
  • SQ-109

パイプライン製品の最新動向

休止状態のプロジェクト

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8283IDB

Summary

Global Markets Direct's, 'Helicobacter pylori Infections - Pipeline Review, H2 2016', provides an overview of the Helicobacter pylori Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Helicobacter pylori Infections
  • The report reviews pipeline therapeutics for Helicobacter pylori Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Helicobacter pylori Infections therapeutics and enlists all their major and minor projects
  • The report assesses Helicobacter pylori Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Helicobacter pylori Infections

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Helicobacter pylori Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Helicobacter pylori Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Helicobacter pylori Infections Overview
  • Therapeutics Development
    • Pipeline Products for Helicobacter pylori Infections - Overview
    • Pipeline Products for Helicobacter pylori Infections - Comparative Analysis
  • Helicobacter pylori Infections - Therapeutics under Development by Companies
  • Helicobacter pylori Infections - Therapeutics under Investigation by Universities/Institutes
  • Helicobacter pylori Infections - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Helicobacter pylori Infections - Products under Development by Companies
  • Helicobacter pylori Infections - Products under Investigation by Universities/Institutes
  • Helicobacter pylori Infections - Companies Involved in Therapeutics Development
    • Daewoong Pharmaceutical Co., Ltd.
    • Debiopharm International SA
    • EpiVax, Inc.
    • Frost Biologic, Inc.
    • ImevaX GmbH
    • ImmunoBiology Limited
    • Recce Pty Ltd
    • RedHill Biopharma Ltd.
    • Sequella, Inc.
    • Sigmoid Pharma Limited
  • Helicobacter pylori Infections - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amoxicillin sodium + omeprazole sodium + rifabutin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Debio-1453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DWJ-1325 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FROST-900 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori [strain Hel-305] (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Helicobacter pylori vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HPi-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RECCE-327 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Helicobacter Pylori Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SQ-109 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Helicobacter pylori Infections - Dormant Projects
  • Helicobacter pylori Infections - Product Development Milestones
    • Featured News & Press Releases
      • Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
      • Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection
      • Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105
      • Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study's Positive Results
      • Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection
      • Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection
      • Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection
      • Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study
      • Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results
      • May 18, 2015: RedHill Biopharma's Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market
      • May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study
      • Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection
      • Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment
      • Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105
      • Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Helicobacter pylori Infections, H2 2016
  • Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Helicobacter pylori Infections - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Helicobacter pylori Infections - Pipeline by Debiopharm International SA , H2 2016
  • Helicobacter pylori Infections - Pipeline by EpiVax, Inc., H2 2016
  • Helicobacter pylori Infections - Pipeline by Frost Biologic, Inc., H2 2016
  • Helicobacter pylori Infections - Pipeline by ImevaX GmbH, H2 2016
  • Helicobacter pylori Infections - Pipeline by ImmunoBiology Limited, H2 2016
  • Helicobacter pylori Infections - Pipeline by Recce Pty Ltd, H2 2016
  • Helicobacter pylori Infections - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Helicobacter pylori Infections - Pipeline by Sequella, Inc., H2 2016
  • Helicobacter pylori Infections - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Helicobacter pylori Infections - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Helicobacter pylori Infections, H2 2016
  • Number of Products under Development for Helicobacter pylori Infections - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top